ImmuPharma (LON:IMM) Trading 19.8% Higher - Time to Buy?

Key Points

• ImmuPharma plc shares rose by 19.8% during mid-day trading, with approximately 20.66 million shares traded, significantly above the average volume.
• The company reported a net margin of 3,519.56% despite a negative return on equity of 131.41% and a PE ratio of -1,463.93.
• ImmuPharma is focusing on peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, aimed at treating Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price traded up 19.8% on Friday . The company traded as high as GBX 13.45 ($0.18) and last traded at GBX 13 ($0.18). 20,660,039 shares traded hands during trading, an increase of 159% from the average session volume of 7,983,476 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Price Performance

The stock's 50-day moving average is GBX 3.12 and its two-hundred day moving average is GBX 2.91. The stock has a market cap of £69.86 million, a P/E ratio of -1,570.67 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.